Navigation Links
Generic Erosion of Established Branded Atypical Antipsychotics Will Cause the Schizophrenia Drug Market To Decline More Than $1 Billion by 2013
Date:12/2/2009

WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of several established branded atypical antipsychotics will cause the schizophrenia drug market to decrease from $6.3 billion in 2008 to $5.2 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Schizophrenia finds that the patent expiries of Janssen's Risperdal Consta and Invega, AstraZeneca's Seroquel, Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify, Eli Lilly's Zyprexa and Pfizer's Geodon/Zeldox will be the key factors driving a 20 percent decrease in the overall schizophrenia drug market. However, as a result of the uptake of emerging therapies -- primarily depot formulations -- the market will increase modestly from $5.2 billion in 2013 to $5.6 billion in 2018.

The launch of new depot formulations of atypical antipsychotics will partially offset the decline in the schizophrenia market and will offer more-convenient treatment options for patients. Janssen's depot formulation of Invega, Invega Sustenna, will experience the greatest market success of all depot formulations, with peak-year major-market sales in excess of $500 million.

"Depot formulations such as Invega Sustenna will offer advantages in dosing and administration compared with the only marketed atypical depot formulation -- Janssen's Risperdal Consta," said Decision Resources Analyst Sandra Chow, M.Sc. "Emerging depot formulations will command premium pricing and, in 2018, will account for nearly one-third of the overall schizophrenia drug market."

Interviewed experts indicate that because most current antipsychotics function through similar mechanisms of action and are not completely effective in all patients, the development of therapies with novel mechanisms of action remains a key unmet need in schizophrenia treatment. Eli Lilly's LY-2140023 will be the first agent with a novel mechanism of action to reach the market, launching in 2013 in the United States and in 2014 in Europe. The report finds that LY-2140023, which will be largely used in conjunction with currently available agents, will provide physicians with an effective new treatment option for patients inadequately controlled on other antipsychotic regimens.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


For more information, contact:

Decision Resources                        Decision Resources, Inc.
Christopher Comfort                       Elizabeth Marshall
781-296-2597                              781-296-2563
ccomfort@dresources.com                   emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
2. Watson Launches Generic Biaxin(R) XL
3. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
4. Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms
5. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
6. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
7. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
8. Bundling Two Generic Low-Cost Heart Drugs Prevents Heart Attack and Stroke in Large, Diverse Population, Observational Clinical Study Shows
9. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
10. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
11. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , Feb 27, 2017 Period October – December ... Operating result amounted to SEK -16.4 (-6.4) million ... per share (-0.22) before and after dilution Cash flow from ... ... to SEK 0.4 (0.4) million Operating result amounted to SEK ...
(Date:2/24/2017)... , Feb. 24, 2017  Today, exocad America ... labs have a new path to produce 510(K) ... Biodenta implant library integrated into exocad DentalCAD software. ... FDA compliant Good Manufacturing Processes (GMP,s) into their ... Biodenta, and complete an audit process. Then, dental labs ...
(Date:2/24/2017)... Research and Markets has announced the addition of the "Global ... report to their offering. ... The Global Wireless Health Market is poised to ... to reach approximately $330.5 billion by 2025. This industry ... segments on global as well as regional levels presented in the ...
Breaking Medicine Technology:
(Date:2/27/2017)... NEW PORT RICHEY, Fla. (PRWEB) , ... February 27, 2017 , ... ... substance use disorder, but concern for women who become dependent on opioid painkillers has ... 400% among female patients, compared to a 237% increase in fatal overdoses in male ...
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar ... analysis as a tool to characterize particle size distributions in the field of ... results and novel scientific findings. It describes methods of optimized and standardized sample ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... rehabilitation and alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , ... its team. The new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation ...
(Date:2/26/2017)... MICHIGAN (PRWEB) , ... February 25, 2017 , ... The ... Kim Jong-un, heightened awareness and concern over nerve agents and the deadly use of ... the human nervous system and how even small doses can be lethal. , Jay ...
(Date:2/26/2017)... York (PRWEB) , ... February 26, 2017 , ... ... products for wholesale distribution in North America, today announced it would be offering ... The company, which prides itself on crafting quality and unique baby clothing/feeding products, ...
Breaking Medicine News(10 mins):